Amgen Ventures, MRL Ventures Fund and Pharmaron contributed to a round that almost doubled the total raised by the bone marrow disease drug developer since 2012.

University of Delaware-backed science incubator Delaware Innovation Space has started a VC vehicle called First Fund offering startups up to $75,000 in convertible notes.

Eli Lilly and GlaxoSmithKline-backed cancer treatment developer Turning Point Therapeutics has filed to raise up to $100m having secured $145m in VC funding.

Pharmaceutical firm Pfizer has acquired a 15% stake in the gene therapy developer along with an exclusive option to fully buy the Novartis-backed company.

The immunotherapy developer, which is majority owned by BGI Group, has secured $17.8m in a GF Securities-led round that will fund clinical work on its lead product candidate.

Brainlab has purchased the surgical robotics technology provider for an undisclosed amount, two years after investing in the company.

BioLeaders is investing $10m in an as yet unnamed spinout from Weizmann Institute of Science working on a genetic drug for cancer.

The former head of Johnson & Johnson's JLabs@TMC incubator has been appointed director of Texas Medical Center's TMC Innovation Institute.

Busy Burr, a founding partner of Humana Health Ventures who featured on GCV’s 2017 and 2018 Powerlists, was named a director at Mr Cooper at the end of February.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.